A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 692-696

  Watari, Hidemichi ^a   Hosaka, Masayoshi ^a   Wakui, Yukio ^b   Nomura, Eiji ^c   Hareyama, Hitoshi ^d   Tanuma, Fumie ^e   Hattori, Rifumi ^f   Azuma, Masaki ^g   Kato, Hidenori ^h   Takeda, Naoki ⁱ   Ariga, Satoshi ^j   Sakuragi, Noriaki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KKR Sapporo Medical Center   (Japan)

^c Ohji General Hospital   (Japan)

^d SAPPORO CITY GENERAL HOSPITAL   (Japan)

^e HAKODATE CENTRAL GENERAL HOSPITAL   (Japan)

^f Obihiro Kosei General Hospital   (Japan)

^g Kushiro Red Cross Hospital   (Japan)

^h HOKKAIDO CANCER CENTER   (Japan)

ⁱ SUNAGAWA CITY MEDICAL CENTER   (Japan)

^j Hokkaido Social Insurance Hospital   (Japan)

more..

Author keywords

Gynecologic cancer; Malignant bowel obstruction; Octreotide; Quality of life

Indexed keywords

OCTREOTIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTESTINE OBSTRUCTION; JAPANESE; NASOGASTRIC TUBE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; GENITAL NEOPLASMS, FEMALE; HUMANS; INTESTINAL OBSTRUCTION; INTUBATION, GASTROINTESTINAL; MIDDLE AGED; NEOPLASM STAGING; OCTREOTIDE; PALLIATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; VOMITING; YOUNG ADULT;

EID: 84863706817     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318244ce93     Document Type: Article

References (13)

1. Beattie GJ, Leonard R, Smyth JF. Bowel obstruction in ovarian carcinoma. A retrospective study and review of the literature. J Palliat Care. 1989;3:275-280.
2. Tunca JC, Buchler DA, Mack EA, et al. The management of ovarian cancer caused bowel obstruction. Gynecol Oncol. 1981;12:186-192.
3. Ripamonti C. Management of bowel obstruction in patients with advanced terminal cancer. Support Care Oncol. 1993;9:10-13.
4. Ripamonti C, De Conno F, Ventafridda V, et al. Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol. 1993;4:15-21.
5. Mercadante S, Maddaloni S. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage. 1992;7:496-499.
6. Mangili G, Franchi M, Mariani A, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 1996;61:345-348.
7. Matulonis UA, Seiden MV, Roche M, et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005;30:563-569.
8. Shima Y, Ohtsu A, Shirao K, et al. Clinical efficacy and safety of octreotide (SMS201-995) in terminally III Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 2008;38:354-359.
9. Baines M, Oliver DJ, Carter RI. Medical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study. Lancet. 1985;2:990-993.
10. Khoo D, Hall E, Motson R, et al. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer. 1994;30 A: 28-30.
11. Ripamonti C, Mercadante S, Groff L, et al. A role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 2000;19:23-34.
12. Mercadante S, Ripamonti C, Casuccio A, et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000;8:188-191.
13. Mangili G, Aletti G, Frigerio L, et al. Palliative care for intestinal obstruction in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15:830-835.